307prisk Factors of Trastuzumab Induced Cardiotoxicity in Her2-positive Early Breast Cancer.
نویسندگان
چکیده
M.A. Sendur1, S. Aksoy2, H. Yorgun3, N. Ozdemir1, F.M. Yilmaz4, O. Yazici5, C. Zungun4, K. Aytemir3, N. Zengin1, M.K. Altundag2 Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, TURKEY Medical Oncology, Hacettepe University Cancer Institute, Ankara, TURKEY Department of Cardiology, Hacettepe University, Ankara, TURKEY Department of Biochemistry, Ankara Numune Education and Research Hospital, Ankara, TURKEY Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, TURKEY
منابع مشابه
Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer
BACKGROUND Trastuzumab therapy given in combination with one of several chemotherapy regimens is currently considered the standard of care for the treatment of early-stage, human epidermal growth factor receptor-2 (HER2) -positive breast cancer. The treatment with trastuzumab is due to a significant impact on the survival part of the standard adjuvant treatment of patients with HER2-positive br...
متن کاملCardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.
Trastuzumab (Herceptin) is a humanised monoclonal antibody that specifically targets HER2-positive breast cancer cells. Safety data collected from pivotal trials with trastuzumab indicate that this therapy is generally well tolerated. However trials of the combination of trastuzumab plus chemotherapy, and in particular chemotherapy with anthracyclines, have revealed an elevated incidence of car...
متن کاملEffectiveness of trastuzumab as adjuvant therapy in patients with early stage breast cancer: A systematic review and meta-analysis
Background: Trastuzumab in combination with chemotherapy has long been established as a standard treatment for HER2-positive patients in early stage breast cancer (BC). The present study aimed at assessing the effectiveness of trastuzumab adjuvant therapy in early stage BC in overall survival (OS) and disease-free survival (DFS). Methods: A systematic review and meta-analysis was ...
متن کاملRole of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer
Approximately 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2) protein, mainly as a result of gene amplification. The receptor tyrosine kinase is believed to play a critical role in the pathogenesis and further proliferation of these tumors. The application of trastuzumab, a humanized monoclonal antibody against the extracellular domain of HER2 protein, to HER2-...
متن کاملHER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer.
The humanized monoclonal antibody pertuzumab prevents the dimerization of HER2 with other HER receptors, in particular the pairing of the most potent signaling heterodimer HER2/HER3, thus providing a potent strategy for dual HER2 inhibition. It binds to the extracellular domain of HER2 at a different epitope than trastuzumab. Pertuzumab and trastuzumab act in a complementary fashion and provide...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Annals of oncology : official journal of the European Society for Medical Oncology
دوره 25 suppl_4 شماره
صفحات -
تاریخ انتشار 2014